Market Closed -
Nasdaq
04:00:00 2024-06-05 pm EDT
|
5-day change
|
1st Jan Change
|
8.07
USD
|
-2.77%
|
|
+0.62%
|
-27.75%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
362.5
|
484.4
|
265.1
|
592.4
|
1,041
|
794
|
-
|
-
|
Enterprise Value (EV)
1 |
362.5
|
484.4
|
265.1
|
592.4
|
487
|
392.8
|
603.9
|
570.2
|
P/E ratio
|
-1.07
x
|
-7.91
x
|
-2.92
x
|
-4.34
x
|
-5.59
x
|
-3.23
x
|
-2.76
x
|
-2.98
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
741
x
|
318
x
|
20.8
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
367
x
|
242
x
|
15
x
|
EV / EBITDA
|
-13.6
x
|
-9.83
x
|
-2.96
x
|
-5.8
x
|
-3.22
x
|
-1.55
x
|
-2.17
x
|
-1.87
x
|
EV / FCF
|
-14.2
x
|
-10.4
x
|
-3.45
x
|
-7.31
x
|
-3.77
x
|
-1.93
x
|
-2.31
x
|
-1.97
x
|
FCF Yield
|
-7.06%
|
-9.57%
|
-29%
|
-13.7%
|
-26.5%
|
-51.8%
|
-43.3%
|
-50.7%
|
Price to Book
|
-
|
-
|
-
|
-
|
1.48
x
|
2.01
x
|
4.72
x
|
4.91
x
|
Nbr of stocks (in thousands)
|
13,789
|
19,879
|
20,282
|
46,537
|
93,206
|
98,384
|
-
|
-
|
Reference price
2 |
26.29
|
24.37
|
13.07
|
12.73
|
11.17
|
8.070
|
8.070
|
8.070
|
Announcement Date
|
3/18/20
|
3/24/21
|
3/24/22
|
3/10/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
1.071
|
2.5
|
38.11
|
EBITDA
1 |
-26.62
|
-49.3
|
-89.66
|
-102.2
|
-151.2
|
-253.3
|
-278.6
|
-305.4
|
EBIT
1 |
-26.64
|
-49.36
|
-89.74
|
-102.2
|
-151.2
|
-251.3
|
-283.5
|
-282.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-23,455.69%
|
-11,339.64%
|
-741.16%
|
Earnings before Tax (EBT)
1 |
-57.2
|
-49.56
|
-90.27
|
-102
|
-138.3
|
-240.1
|
-278.6
|
-282.7
|
Net income
1 |
-57.42
|
-49.5
|
-90.12
|
-102
|
-142.2
|
-238.6
|
-286.7
|
-292.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-22,267.08%
|
-11,466.76%
|
-767.51%
|
EPS
2 |
-24.49
|
-3.080
|
-4.480
|
-2.930
|
-2.000
|
-2.495
|
-2.921
|
-2.709
|
Free Cash Flow
1 |
-25.6
|
-46.37
|
-76.84
|
-81.1
|
-129.2
|
-203.5
|
-261.4
|
-289.3
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-18,993.31%
|
-10,456.96%
|
-759.12%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/20
|
3/24/21
|
3/24/22
|
3/10/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.625
|
0.625
|
-
|
-
|
EBITDA
|
-
|
-
|
-24.72
|
-
|
-
|
-
|
-
|
-39.34
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-26.24
|
-25.11
|
-24.74
|
-27.04
|
-25.36
|
-28.52
|
-42.13
|
-39.34
|
-41.21
|
-57.28
|
-59.67
|
-70.29
|
-64.09
|
-69.78
|
-71.81
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,246.41%
|
-10,254.51%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-26.44
|
-25.56
|
-25.05
|
-26.8
|
-24.59
|
-28.84
|
-38.39
|
-34.72
|
-36.37
|
-51.58
|
-56.01
|
-70.91
|
-61.57
|
-67.12
|
-69.88
|
Net income
1 |
-63.83
|
-25.56
|
-25.05
|
-26.8
|
-24.6
|
-28.84
|
-38.39
|
-34.72
|
-40.24
|
-51.68
|
-56.3
|
-67.98
|
-62.67
|
-67.12
|
-69.88
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-10,876.84%
|
-10,027.27%
|
-
|
-
|
EPS
2 |
-1.300
|
-1.260
|
-1.230
|
-0.5700
|
-0.4800
|
-0.5400
|
-0.5200
|
-0.4500
|
-0.5000
|
-0.5400
|
-0.5786
|
-0.6943
|
-0.6371
|
-0.6812
|
-0.7035
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/22
|
5/11/22
|
8/11/22
|
11/10/22
|
3/10/23
|
5/8/23
|
8/9/23
|
11/9/23
|
2/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
554
|
401
|
190
|
224
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-25.6
|
-46.4
|
-76.8
|
-81.1
|
-129
|
-204
|
-261
|
-289
|
ROE (net income / shareholders' equity)
|
-155%
|
-33.8%
|
-54.8%
|
-73.5%
|
-41.3%
|
-56%
|
-90.1%
|
-173%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
7.540
|
4.020
|
1.710
|
1.640
|
Cash Flow per Share
2 |
-10.90
|
-2.870
|
-3.820
|
-0.7800
|
-1.820
|
-2.180
|
-2.770
|
-
|
Capex
1 |
0.14
|
0.13
|
0.06
|
0.01
|
0
|
0
|
2.03
|
3.06
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
0.37%
|
81.3%
|
8.03%
|
Announcement Date
|
3/18/20
|
3/24/21
|
3/24/22
|
3/10/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
8.07
USD Average target price
31.11
USD Spread / Average Target +285.52% Consensus |
1st Jan change
|
Capi.
|
---|
| -27.75% | 794M | | +18.72% | 125B | | +14.53% | 109B | | -2.88% | 24.74B | | +2.18% | 22.67B | | -10.09% | 18.14B | | -41.04% | 16.67B | | -11.83% | 16.64B | | +1.46% | 13.45B | | +24.22% | 11.32B |
Bio Therapeutic Drugs
|